A majority of familial Pulmonary arterial hypertension (PAH) patients, over 70%, and a significant proportion of idiopathic PAH patients, over 20%, possess heterozygous mutations that impair BMPR2 activity. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.